TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK
Background Although rare, uterine sarcomas account for a high proportion of uterine cancer mortality. Treatment options and robust trial data are limited.Objectives The TOURISM study (Treatment Outcomes in UteRIne SarcoMa) is a UK-wide study by the National Oncology Trainees Collaborative for Health...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/12/e094838.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823865124185702400 |
|---|---|
| author | Rebekah Webb Mohammed Al-Zubaidi Mark A Baxter Karin Purshouse James Robertson Helen Creedon Katherine Fair Asma Sarwar Laura Hannington Adam L Peters Samuel Mcinerney Karen E Mactier Georgina E Wood Mai K Bishr Leonie Eastlake Katharine Lankester Alison L Stillie |
| author_facet | Rebekah Webb Mohammed Al-Zubaidi Mark A Baxter Karin Purshouse James Robertson Helen Creedon Katherine Fair Asma Sarwar Laura Hannington Adam L Peters Samuel Mcinerney Karen E Mactier Georgina E Wood Mai K Bishr Leonie Eastlake Katharine Lankester Alison L Stillie |
| author_sort | Rebekah Webb |
| collection | DOAJ |
| description | Background Although rare, uterine sarcomas account for a high proportion of uterine cancer mortality. Treatment options and robust trial data are limited.Objectives The TOURISM study (Treatment Outcomes in UteRIne SarcoMa) is a UK-wide study by the National Oncology Trainees Collaborative for Healthcare Research which aimed to characterise this patient cohort.Design A retrospective descriptive cohort study. Patients with carcinosarcomas/mixed Mullerian tumours, non-uterine gynaecological sarcomas and uterine metastases were excluded. Routine clinical data, including general patient demographics, diagnosis, treatment and outcomes, were collated and pseudonymised.Setting Patients diagnosed with uterine sarcoma in the UK National Health Service between 1 January 2008 and 31 December 2017 were identified from electronic records.Participants A total of 406 patients from eight centres were eligible for inclusion.Results The median age at diagnosis was 56 years, with leiomyosarcoma the most common diagnosis (54.4%). The majority (57.9%) were diagnosed at the International Federation of Gynecology and Obstetrics stage I, with 19.7% diagnosed at stage IV. Nearly half (45.2%) of the patients received at least one line of chemotherapy, of which most (81.0%) received doxorubicin first-line. In the stage I group 7.4% received adjuvant chemotherapy and 15.0% received adjuvant radiotherapy. Median overall survival was 37 months; however, survival varied significantly by stage at diagnosis (stage I: 105 months; stage II: 33 months; stage III: 19 months; stage IV: 14 months).Conclusions Our data highlight the diversity in patient management in uterine sarcoma and a marked survival advantage for patients diagnosed with stage I disease. These data highlight the importance of a multidisciplinary approach and describe real-world trends in systemic therapies, radiotherapy and surgical treatment in this rare cancer type. |
| format | Article |
| id | doaj-art-a4f6e59e92ac4708b70ebfe05f6ce305 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-a4f6e59e92ac4708b70ebfe05f6ce3052025-02-08T13:45:13ZengBMJ Publishing GroupBMJ Open2044-60552024-12-01141210.1136/bmjopen-2024-094838TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UKRebekah Webb0Mohammed Al-Zubaidi1Mark A Baxter2Karin Purshouse3James Robertson4Helen Creedon5Katherine Fair6Asma Sarwar7Laura Hannington8Adam L Peters9Samuel Mcinerney10Karen E Mactier11Georgina E Wood12Mai K Bishr13Leonie Eastlake14Katharine Lankester15Alison L Stillie16Royal Derby Hospital, Derby, UKWeston Park Hospital, Sheffield, UKNinewells Hospital and Medical School, Dundee, UKEdinburgh Cancer Centre, Western General Hospital, Edinburgh, UKBeatson West of Scotland Cancer Centre, Glasgow, UKEdinburgh Cancer Centre, Western General Hospital, Edinburgh, UKBeatson West of Scotland Cancer Centre, Glasgow, UKRadiotherapy, University College Hospital, London, UKBeatson West of Scotland Cancer Centre, Glasgow, UKThe Beatson Institute for Cancer Research, Glasgow, UKBeatson West of Scotland Cancer Centre, Glasgow, UKInstitute of Cancer Sciences, University of Glasgow, Glasgow, UKUniversity College London Hospitals NHS Foundation Trust, London, UKThe Institute of Cancer Research, London, UKRoyal Cornwall Hospital, Truro, UKRoyal Sussex County Hospital, Brighton, UKEdinburgh Cancer Centre, Western General Hospital, Edinburgh, UKBackground Although rare, uterine sarcomas account for a high proportion of uterine cancer mortality. Treatment options and robust trial data are limited.Objectives The TOURISM study (Treatment Outcomes in UteRIne SarcoMa) is a UK-wide study by the National Oncology Trainees Collaborative for Healthcare Research which aimed to characterise this patient cohort.Design A retrospective descriptive cohort study. Patients with carcinosarcomas/mixed Mullerian tumours, non-uterine gynaecological sarcomas and uterine metastases were excluded. Routine clinical data, including general patient demographics, diagnosis, treatment and outcomes, were collated and pseudonymised.Setting Patients diagnosed with uterine sarcoma in the UK National Health Service between 1 January 2008 and 31 December 2017 were identified from electronic records.Participants A total of 406 patients from eight centres were eligible for inclusion.Results The median age at diagnosis was 56 years, with leiomyosarcoma the most common diagnosis (54.4%). The majority (57.9%) were diagnosed at the International Federation of Gynecology and Obstetrics stage I, with 19.7% diagnosed at stage IV. Nearly half (45.2%) of the patients received at least one line of chemotherapy, of which most (81.0%) received doxorubicin first-line. In the stage I group 7.4% received adjuvant chemotherapy and 15.0% received adjuvant radiotherapy. Median overall survival was 37 months; however, survival varied significantly by stage at diagnosis (stage I: 105 months; stage II: 33 months; stage III: 19 months; stage IV: 14 months).Conclusions Our data highlight the diversity in patient management in uterine sarcoma and a marked survival advantage for patients diagnosed with stage I disease. These data highlight the importance of a multidisciplinary approach and describe real-world trends in systemic therapies, radiotherapy and surgical treatment in this rare cancer type.https://bmjopen.bmj.com/content/14/12/e094838.full |
| spellingShingle | Rebekah Webb Mohammed Al-Zubaidi Mark A Baxter Karin Purshouse James Robertson Helen Creedon Katherine Fair Asma Sarwar Laura Hannington Adam L Peters Samuel Mcinerney Karen E Mactier Georgina E Wood Mai K Bishr Leonie Eastlake Katharine Lankester Alison L Stillie TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK BMJ Open |
| title | TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK |
| title_full | TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK |
| title_fullStr | TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK |
| title_full_unstemmed | TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK |
| title_short | TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK |
| title_sort | tourism study treatment outcomes in uterine sarcoma a 10 year retrospective evaluation of practice in the uk |
| url | https://bmjopen.bmj.com/content/14/12/e094838.full |
| work_keys_str_mv | AT rebekahwebb tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk AT mohammedalzubaidi tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk AT markabaxter tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk AT karinpurshouse tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk AT jamesrobertson tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk AT helencreedon tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk AT katherinefair tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk AT asmasarwar tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk AT laurahannington tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk AT adamlpeters tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk AT samuelmcinerney tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk AT karenemactier tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk AT georginaewood tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk AT maikbishr tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk AT leonieeastlake tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk AT katharinelankester tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk AT alisonlstillie tourismstudytreatmentoutcomesinuterinesarcomaa10yearretrospectiveevaluationofpracticeintheuk |